

Alexander M K Rothman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6150832/publications.pdf>

Version: 2024-02-01

43
papers

1,328
citations

516710

16
h-index

361022

35
g-index

45
all docs

45
docs citations

45
times ranked

2095
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 1 | The effect of interleukin-1 receptor antagonist therapy on markers of inflammation in non-ST elevation acute coronary syndromes: the MRC-ILA Heart Study. <i>European Heart Journal</i> , 2015, 36, 377-384. | 2.2 | 243 |
| 2 | Magnetic Resonance Imaging in the Prognostic Evaluation of Patients with Pulmonary Arterial Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 196, 228-239. | 5.6 | 122 |
| 3 | MicroRNA-140-5p and SMURF1 regulate pulmonary arterial hypertension. <i>Journal of Clinical Investigation</i> , 2016, 126, 2495-2508. | 8.2 | 119 |
| 4 | Older Adults™ Experiences Using a Commercially Available Monitor to Self-Track Their Physical Activity. <i>JMIR MHealth and UHealth</i> , 2016, 4, e35. | 3.7 | 117 |
| 5 | Hemodynamic, Functional, and Clinical Responses to Pulmonary Artery Denervation in Patients With Pulmonary Arterial Hypertension of Different Causes. <i>Circulation: Cardiovascular Interventions</i> , 2015, 8, e002837. | 3.9 | 103 |
| 6 | Identification of Cardiac Magnetic Resonance Imaging Thresholds for Risk Stratification in Pulmonary Arterial Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 201, 458-468. | 5.6 | 99 |
| 7 | Pulmonary Artery Denervation Reduces Pulmonary Artery Pressure and Induces Histological Changes in an Acute Porcine Model of Pulmonary Hypertension. <i>Circulation: Cardiovascular Interventions</i> , 2015, 8, e002569. | 3.9 | 66 |
| 8 | Intravascular Ultrasound Pulmonary Artery Denervation to Treat Pulmonary Arterial Hypertension (TROPHY1). <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 989-999. | 2.9 | 47 |
| 9 | Blood flow suppresses vascular Notch signalling via dll4 and is required for angiogenesis in response to hypoxic signalling. <i>Cardiovascular Research</i> , 2013, 100, 252-261. | 3.8 | 45 |
| 10 | klf2ash317 Mutant Zebrafish Do Not Recapitulate Morpholino-Induced Vascular and Haematopoietic Phenotypes. <i>PLoS ONE</i> , 2015, 10, e0141611. | 2.5 | 40 |
| 11 | Cardiac magnetic resonance identifies raised left ventricular filling pressure: prognostic implications. <i>European Heart Journal</i> , 2022, 43, 2511-2522. | 2.2 | 32 |
| 12 | A diagnostic miRNA signature for pulmonary arterial hypertension using a consensus machine learning approach. <i>EBioMedicine</i> , 2021, 69, 103444. | 6.1 | 30 |
| 13 | Meta-analysis of echocardiographic quantification of left ventricular filling pressure. <i>ESC Heart Failure</i> , 2021, 8, 566-576. | 3.1 | 27 |
| 14 | Differential IL-1 signaling induced by BMPR2 deficiency drives pulmonary vascular remodeling. <i>Pulmonary Circulation</i> , 2017, 7, 768-776. | 1.7 | 26 |
| 15 | A therapeutic antibody targeting osteoprotegerin attenuates severe experimental pulmonary arterial hypertension. <i>Nature Communications</i> , 2019, 10, 5183. | 12.8 | 22 |
| 16 | IL-6 in pulmonary hypertension: why novel is not always best. <i>European Respiratory Journal</i> , 2020, 55, 2000314. | 6.7 | 21 |
| 17 | Interleukin-1 beta inhibition with canakinumab and reducing lung cancer subset analysis of the canakinumab anti-inflammatory thrombosis outcome study trial (CANTOS). <i>Journal of Thoracic Disease</i> , 2018, 10, S3084-S3087. | 1.4 | 17 |
| 18 | Role of biomarkers in evaluation, treatment and clinical studies of pulmonary arterial hypertension. <i>Pulmonary Circulation</i> , 2020, 10, 1-17. | 1.7 | 16 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | Right ventricular remodelling in pulmonary arterial hypertension predicts treatment response. <i>Heart</i> , 2022, 108, 1392-1400. | 2.9 | 15 |
| 20 | Age-associated changes in 4D flow CMR derived Tricuspid Valvular Flow and Right Ventricular Blood Flow Kinetic Energy. <i>Scientific Reports</i> , 2020, 10, 9908. | 3.3 | 13 |
| 21 | Emerging therapies for right ventricular dysfunction and failure. <i>Cardiovascular Diagnosis and Therapy</i> , 2020, 10, 1735-1767. | 1.7 | 13 |
| 22 | Maximal Exercise Testing Using the Incremental Shuttle Walking Test Can Be Used to Risk-Stratify Patients with Pulmonary Arterial Hypertension. <i>Annals of the American Thoracic Society</i> , 2021, 18, 34-43. | 3.2 | 13 |
| 23 | Cardiovascular magnetic resonance predicts all-cause mortality in pulmonary hypertension associated with heart failure with preserved ejection fraction. <i>International Journal of Cardiovascular Imaging</i> , 2021, 37, 3019-3025. | 1.5 | 12 |
| 24 | Right Ventricular Adaptation Assessed Using Cardiac Magnetic Resonance Predicts Survival in Pulmonary Arterial Hypertension. <i>JACC: Cardiovascular Imaging</i> , 2021, 14, 1271-1272. | 5.3 | 11 |
| 25 | Arrhythmic Burden and Outcomes in Pulmonary Arterial Hypertension. <i>Frontiers in Medicine</i> , 2019, 6, 169. | 2.6 | 10 |
| 26 | Training and clinical testing of artificial intelligence derived right atrial cardiovascular magnetic resonance measurements. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2022, 24, 25. | 3.3 | 8 |
| 27 | Clinical predictors of all-cause mortality in patients presenting to specialist heart failure clinic with raised NT-proBNP and no heart failure. <i>ESC Heart Failure</i> , 2020, 7, 1791-1800. | 3.1 | 7 |
| 28 | Imaging and Risk Stratification in Pulmonary Arterial Hypertension: Time to Include Right Ventricular Assessment. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 797561. | 2.4 | 7 |
| 29 | Investigating Microtemporal Processes Underlying Health Behavior Adoption and Maintenance: Protocol for an Intensive Longitudinal Observational Study. <i>JMIR Research Protocols</i> , 2022, 11, e36666. | 1.0 | 6 |
| 30 | The Canakinumab Antiinflammatory Thrombosis Outcome Study trial—the starting gun has fired. <i>Journal of Thoracic Disease</i> , 2017, 9, 4922-4925. | 1.4 | 5 |
| 31 | Positioning imatinib for pulmonary arterial hypertension: A phase I/II design comprising dose finding and single-arm efficacy. <i>Pulmonary Circulation</i> , 2021, 11, 1-12. | 1.7 | 5 |
| 32 | miRNA-140-5p: new avenue for pulmonary arterial hypertension drug development?. <i>Epigenomics</i> , 2016, 8, 1311-1313. | 2.1 | 4 |
| 33 | Prolonged enoxaparin therapy compared with standard-of-care antithrombotic therapy in opiate-treated patients undergoing primary percutaneous coronary intervention. <i>Platelets</i> , 2021, 32, 555-559. | 2.3 | 3 |
| 34 | T5 Opg Regulates Pulmonary Arterial Smooth Muscle Cell Proliferation And The Expression Of Pah-associated Genes Via Fas. <i>Thorax</i> , 2014, 69, A2-A3. | 5.6 | 1 |
| 35 | microRNA-140-5p and SMURF1 Regulate Pulmonary Arterial Hypertension. <i>Heart</i> , 2016, 102, A147-A147. | 2.9 | 1 |
| 36 | Prognostic Significance of Reduced Blood Pressure Response to Exercise in Pediatric Pulmonary Arterial Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 196, 1478-1481. | 5.6 | 1 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 37 | 124â€¦Comparing the safety and feasibility of implanting pulmonary artery pressure monitors via the internal jugular vein compared to standard femoral venous access in patients with pulmonary arterial hypertension. , 2021, , . | | 1 |
| 38 | Response to Letter Regarding Article, â€œHemodynamic, Functional, and Clinical Responses to Pulmonary Artery Denervation in Patients With Pulmonary Arterial Hypertension of Different Causes: Phase II Results From the Pulmonary Artery Denervation-1 Studyâ€• Circulation: Cardiovascular Interventions, 2016, 9, e003463. | 3.9 | 0 |
| 39 | 25â€¦Mitral inflow velocity encoded imaging by CMR for the assessment of left ventricular haemodynamics. , 2019, , . | | 0 |
| 40 | 26â€¦A non-invasive CMR assessment for predicting mean pulmonary artery pressure in pulmonary hypertension. , 2019, , . | | 0 |
| 41 | 27â€¦Mixed venous oxygen levels in pulmonary hypertension is associated with right heart multi-parametric assessment. , 2019, , . | | 0 |
| 42 | 121â€¦Effect of UK COVID-19 public health measures on activity and quality of life in patients with pulmonary arterial hypertension. , 2021, , . | | 0 |
| 43 | Percent-predicted incremental shuttle walking test distance stratifies risk in pulmonary arterial hypertension. , 2020, , . | | 0 |